Business
Billy Evans’ ‘Theranos 2.0’ startup has patents, investors, and a missing CTO—but no product
Headline as filed by Fortune.
Compare coverage — 1 report
| Publisher | Headline | Summary | Published | Detected | Delay | Source | Status |
|---|---|---|---|---|---|---|---|
| Fortune | Billy Evans’ ‘Theranos 2.0’ startup has patents, investors, and a missing CTO—but no product |
As You Can See Everything turns Billy Evans into the year’s most unlikely documentary villain, his Austin startup Haemanthus faces a simple question: What has it built? |
0m | fortune.com | First |
Headlines and summaries belong to the publisher named beside them. “Published” is what their feed stated; “detected” is when PageNews first held the report. Delay is measured from the earliest report on this event and describes timing only.
Reader comments
Comments are written by readers. PageNews does not check them and does not stand behind them, and a name here is a name someone typed, not a person we have identified.
Nobody has commented on this story yet.